Get started
Author

Dominick L. Auci

Observed names: D L Auci, Dominick Auci, Dominick L Auci, Dominick L. Auci
ORCID: 0000-0001-5315-9873
Observed ORCID: 0000-0001-5315-9873
OpenAlex ID: A5007373812
HIV Type 1-Specific IgE in Serum of Long-Term Surviving Children Inhibits HIV Type 1 Production in Vitro
2002 · Michael G. Pellegrino, Martin H. Bluth, et al. · AIDS Research and Human Retroviruses · 30
Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease
2015 · Thomas F. Conway, Laura Hammer, et al. · Journal of Crohn s and Colitis · 28
Orally delivered all-trans-retinoic acid- and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice
2019 · Ivan Koprivica, Dragica Gajic, et al. · European Journal of Pharmacology · 26
Control of IgE responses
1993 · Dominick L. Auci, Seto M. Chice, et al. · Immunopharmacology · 14
16α-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs
2009 · F Nicoletti, D Conrad, et al. · Clinical & Experimental Immunology · 13
Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease
2018 · Dominick L Auci, Nejat K Egilmez, et al. · Journal of Gastroenterology Pancreatology & Liver Disorders · 10
PDF
Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis
2021 · Ferdinando Nicoletti, Laura Hammer, et al. · Inflammatory Bowel Diseases · 8
Synergy of Transforming Growth Factor Beta 1 and All Trans Retinoic Acid in the Treatment of Inflammatory Bowel Disease: Role of Regulatory T cells
2016 · Dominick L. Auci · Journal of Gastroenterology Pancreatology & Liver Disorders · 8
PDF
Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease
2020 · Laura Hammer, Stacia Furtado, et al. · World Journal of Gastrointestinal Pharmacology and Therapeutics · 7
Control of IgE Responses. V. Oral Administration of a Synthetic Derivative of the Inner Bacterial Cell Wall (SDZ 280.636) to Sensitized Mice Induces Isotype Specific Suppression of Peak Hapten Specific IgE Antibody Forming Cell Responses, Serum IgE Levels and Immediate Hypersensitivity Responses
1998 · Dominick L. Auci, Gary I. Kleiner, et al. · Immunological Investigations · 7
Peyer's patches and mesenteric lymph nodes are the sites of first appearance of IgE bearing B lymphocytes and hapten specific IgE antibody forming cells in BPO-KLH sensitized mice.
1992 · D L Auci, S M Chice, et al. · PubMed · 3
Clinical Application of Plasmid-Based Cancer Vaccines
2013 · Dominick L. Auci, Denise L. Cecil, et al. · Elsevier eBooks · 2
IFN-α-mediated suppression of low-affinity Fc receptors on Peyer’s patch lymphocytes and augmentation of soluble CD23: implications for IgE responses
1996 · Hanan Miller, Martin H Bluth, et al. · Journal of Leukocyte Biology · 2
Suppression of human IgE antibody forming cell responses by IL-6
1993 · Gary I Kleiner, Dominick L Auci, et al. · Journal of Leukocyte Biology · 2
Control of IgE responses
1989 · Helen G. Durkin, Dominick L. Auci, et al. · Clinical Immunology and Immunopathology · 2
Dysregulated Proteolysis in Aids
1992 · Dominick L. Auci, Helen G. Durkin, et al. · Immunological Investigations · 1
All-Trans Retinoic Acid in Rodent Models of Autoimmune Diabetes: Clinical Potential of Targeted Drug Delivery
2026 · Benjamin Green, Dominick L. Auci · Canadian Journal of Diabetes
Pharmacokinetics and Pharmacodynamics of Recombinant Human Interleukin 12 in Dog and Rabbit Models of Toxicity
2025 · Benjamin D. Green, Peter C. Soema, et al. · Journal of Applied Toxicology
PDF
Chemical carcinogens used to induce spontaneous tumors may suppress tumor specific T-cell immunity
2013 · Dan Herendeen, Ekram Gad, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 19
Citation count: 163
H-index: 8
I10-index: 6
Year
Topic
Type